Genprex (GNPX) Featured in Publication on Advances in Potential Breast Cancer Treatments
September 25 2019 - 8:30AM
via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its
placement in an editorial published by NetworkNewsWire ("NNW"), a
multifaceted financial news and publishing company for private and
public entities.
To view the full publication, titled “Gene Therapies with
Potential to Conquer Tough-to-Tackle Breast Cancers,” visit:
http://nnw.fm/pNKm2
Advances in biotechnology look to deliver promising new treatment
options against breast cancer. Breast cancer is one of the most
widely prevalent cancers in the world. Accounting for a quarter of
all cancers in women worldwide, as well as a number of cases in
men, it kills over half a million people every year.“Disruptive”
isn’t a term that’s often applied to medicine, where the aim is to
avoid disrupting the health of the human body. But technology such
as Genprex Inc.’s (NASDAQ:GNPX)
Oncoprex(TM) immunogene therapy is disruptive precisely because it
could improve doctors’ ability to preserve health. It may also
change the course of cancer, as new technology often opens up new
possibilities. |
About Genprex Inc.
Genprex Inc. is a clinical-stage, gene-therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex(TM)
immunogene therapy for non-small cell lung cancer (NSCLC).
Genprex’s platform technologies are designed to administer
cancer-fighting genes by encapsulating them into nanoscale hollow
spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express
proteins that are missing or found in low quantities. Oncoprex has
a multimodal mechanism of action whereby it interrupts
cell-signaling pathways that cause replication and proliferation of
cancer cells, re-establishes pathways for apoptosis, or programmed
cell death, in cancer cells, and modulates the immune response
against cancer cells. Oncoprex has also been shown to block
mechanisms that create drug resistance. Visit the company’s web
site at www.genprex.com or follow Genprex on Twitter
at twitter.com/genprex, Facebook
at facebook.com/genprexinc and LinkedIn
at linkedin.com/company/genprex.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content
distribution company that provides (1) access to a network of wire
services via NetworkWire to reach all target markets,
industries and demographics in the most effective manner possible,
(2) article and editorial syndication to 5,000+ news outlets, (3)
enhanced press release services to ensure maximum impact, (4)
social media distribution via the Investor Brand Network (IBN) to
nearly 2 million followers, (5) a full array of corporate
communications solutions, and (6) a total news coverage solution
with NNW Prime. As a multifaceted organization with an extensive
team of contributing journalists and writers, NNW is uniquely
positioned to best serve private and public companies that desire
to reach a wide audience of investors, consumers, journalists and
the general public. By cutting through the overload of information
in today’s market, NNW brings its clients unparalleled visibility,
recognition and brand awareness. NNW is where news, content and
information converge. For more information, please visit
https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications:
NetworkWire (NW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkWire.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024